Cookies on PerkinElmer
PerkinElmer uses cookies to ensure that we give you the best experience possible on our website. This may include cookies from third party websites. If you continue without changing your settings, we will assume that you consent to receive cookies from this website. You can change your cookie settings at any time. To learn more, please review our cookie policy, which includes information on how to manage your cookies.

Working with Serum and Other Biological Matrices in Alpha Assays

Overview


AlphaLISA® is a bead based assay technology that can be used for immunoassays in a microplate format. A key feature of this assay is that it is a homogeneous, or a no wash assay. This feature combined with its sensitivity and high throughput capabilities make Alpha an assay format choice for many research applications. As many researchers wish to apply this technology to samples containing serum, the below content will serve as a guide to optimizing this type of assay.

Some topics that will be considered include:

  • Clinical and pre-clinical studies using serum or blood samples
  • Hemolyzed samples and potential for sample interference
  • Finding a suitable matrix for your standard curve

Both serum and plasma originate from whole blood. Plasma is richer than serum as it contains everything but cells, including fibrinogen and coagulation factors. Researchers may wish to harvest plasma and use agents such as heparin or chelators such as EDTA to prevent blood clotting. Both EDTA and heparin were shown not to affect the Alpha Technology. Serum is more stable and more uniform. Other biological fluids such as cerebrospinal fluid (CSF), bronchoaveolar lavage fluid (BALF), amniotic fluid (AF), saliva or urine are often used to measure biomarkers. Each of these fluids has a unique protein composition and will require specific validation. The goal of the document is to guide you through this specific validation approach.

Working with a complex sample such as serum or CSF may sometimes result in decreased assay sensitivity. However, in most cases, working with these biological matrices is successful if the appropriate procedures are followed.

Top


Matrix Importance


For quantitation of an analyte in your samples, it is necessary to create a standard curve of your analyte in a matrix that closely matches your samples. For example, if you are working with serum samples, you will need to create a standard curve of your analyte in analyte-depleted serum or something similar, such as fetal bovine serum (FBS). A spike-and-recovery experiment should be performed to assess whether a proposed matrix is suitable for your sample type. Table1 provides some examples of possible matrices.

Sample typePossible matrices (diluents) for standard curve
SerumFBS (or analyte-depleted serum)
Cell supernatantThe same culture media as used to treat your cells
Cell lysateLysis buffer (we recommend AlphaLISA lysis buffer, #AL003, for creating lysates)
Unusual sample types (cerebrospinal fluid, amniotic fluid, etc.)Various diluents should be tested. In some cases, where a perfect match for the fluid cannot be found, sample dilution may be required. For example, you may need to dilute your sample 2-fold in 1X PBS + 0.1% BSA, then run your standard curve in 1X PBS + 0.1% BSA.

Table 1: Possible matrices for standard curve by sample type.

There is a correlation between recovery and matrix. When the matrix for your standard matches the sample matrix, the percentage of recovery is better. Figures 1 & 2 illustrate matrix importance and percent recovery. It is important that the matrix should be as close to the sample as possible.

Fig1EGFR 
Sample in immunoassay bufferSpiking conc. (pg/mL)Detected (pg/mL)% recovery
150,00039,99680
210,00010,017100
31006262
Sample in RPMI + 10% FBSSpiking conc. (pg/mL)Detected (pg/mL)% recovery
450,00020,01640
510,0004,84748
6100not detectable
Figure 1: A hEGFR detection assay with a standard curve prepared with Immunoassay Buffer (IAB). Data show comparative values of percent recovery with two different sample matrices. As the standard curve was prepared in IAB, the percent recovery is better for the IAB samples, as compared to the sample prepared with RPMI + 10% FBS.

In Figure 2, the standard curve was instead run in RPMI + 10% FBS. Data show percent recoveries are better with spike-ins prepared in RPMI + 10% FBS.

Fig2EGFR 
Sample in immunoassay bufferSpiking conc. (pg/mL)Detected (pg/mL)% recovery
150,00074,943150
210,00015,331153
3100161161
Sample in RPMI + 10% FBSSpiking conc. (pg/mL)Detected (pg/mL)% recovery
450,00048,44097
510,0009,93599
61005757
Figure 2. The standard curve prepared with RPMI + 10% FBS. Data show only the spike-in concentrations made with RPMI + 10% FBS showed acceptable recoveries; the ones prepared in IAB did not.

In a third experiment, a standard curve for human IL6 was performed in both IAB and FBS. The results are shown in Figure 3.

Fig3IL6v2 
Figure 3. The human IL-6 standard curve was prepared and plotted in both immunoassay buffer and FBS. The curve in FBS shifted to the right, which indicates the reason for different percent recoveries in the different matrices.

There are several standard curve matrix options that can be used when working with serum samples in an Alpha format. These include:

  • Using FBS with or without sample dilution
  • Preparing analyte-depleted serum
  • Buying or custom requesting analyte depleted serum (companies such as Scipac® sell analyte-depleted serum)
  • Using charcoal-stripped serum as a matrix for some analytes
  • Pooled normal serum may be used (Petersen et al. 2010) only if it does not contain a detectable level of analyte being tested

Please refer to our application note regarding Analyte Depletion of Serum for AlphaLISA.

Top


Potential For Sample Interference


When working with serum or plasma, hemolysis is a factor to consider. Hemoglobin absorbs light in the same range as Alpha beads emit light, and can cause interference.

Figure 4 shows different wells with varying amounts of hemoglobin spiked in immunoassay buffer. Based on normal red blood cell (RBC) counts and hemoglobin content in a RBC, the spiked hemoglobin amounts were converted to the approximate hemolysis percentage of RBC. This is a visual representation comparing the amount of hemoglobin and the percent hemolysis in regards to well color.

alpha_hemolysis_ASK.JPG
Figure 4. Comparison between the amount of hemoglobin added as it correlates to the percentage of hemolysis with an AlphaLISA assay.

In order to better determine the effect of hemoglobin on an AlphaLISA assay, a sample was spiked with increasing concentrations of hemoglobin and was measured using the Human Amyloid β 1-40 Immunoassay Kit. The assay was performed as stated in the manual using 5 μl of sample, 20 μl AlphaLISA Acceptor beads/biotinylated antibody and 25 μl of Donor beads.

  • The buffer was spiked with 16,000 pg/mL of Aβ 1-40 and increasing concentrations of hemoglobin
  • The plates were read with an EnVision® 2104 Multilabel plate reader HTS with Alpha option
  • The interpolated values (as shown in Table 2) were determined from the Immunoassay Buffer (IAB) standard curve
Hb (mg/mL)% hemolysisInterpolated (pg/mL)% recovery
0.00.0%16,544100
0.90.6%18,729113
1.91.3%16,740101
3.82.5%13,80583
7.55.0%7,19844

Table 2: Percent recovery for assay samples with varying amounts of hemoglobin. With the addition of 3.8 mg/mL hemoglobin, the percent recovery was 83%. Therefore, a sample containing up to 3.8 mg/mL of hemoglobin, or approximately equivalent to 2.5% hemolysis, may be measured using the AlphaLISA Amyloid β 1-40 kit.

For key AlphaLISA references where serum samples were used, please refer to the References and Citations section following.

Other components of a sample matrix can also potentially interfere with the assay. Interference may result from cross-reactivity of antibodies to a component in the serum sample, depletion of the spiked analyte, or variable levels of IgG, albumin or other proteins.

Serum often contains high concentrations of many components including:

  • Hemoglobin
  • Bilirubin
  • Transferrin
  • IgG and other immunoglobulins
  • Triglycerides and other lipids
  • Biotin and biotinylated proteins
  • Binding proteins/Receptors
  • Related immunogens detected by either one antibody or two antibodies

Reducing sample to sample variability is a critical step in optimizing an AlphaLISA assay using serum samples. There are several factors to examine when attempting to improve percent recovery for an assay. Some suggestions to improve percent recovery include but are not limited to:

  • Diluting the serum samples 2X with FBS
  • Removing IgG
  • Reducing heterophilic interference by using commercial blockers
serum_figure_5_ASK.jpg
Figure 5. The good recoveries obtained for TNFα with a 1/2 diluted pooled serum as a matrix.

The above experiment was repeated using insulin instead of TNFα, as shown in Figure 6.

serum_figure_6_ASK.jpg
Figure 6. Good insulin recovery obtained using 1/2 diluted serum as a matrix.

As we have previously mentioned, serum is made up of many biological components that could potentially interfere with an assay. When using serum samples with the AlphaLISA kits, dilutions may need to be made based on kit parameters. In most cases, potential interference issues can be resolved by diluting the sample or changing the assay buffer.

Top


Identifying Diluents For Any Matrix


The following section describes how to identify a correct diluent for complex sample matrices based on examples from various animal fluids. There were three cytokines selected: IL6, TNFα, and MCP-1 (CCL2). The four sample matrices selected were mouse serum, mouse bronchial lavage fluid (BALF), rat cerebrospinal fluid (CSF) and rat amniotic fluid (AF). These results may also be found in the poster Detecting cytokines in animal fluids.

The assay was performed as indicated in the manual. The protocol is listed below along with the calibration curve for mouse MCP-1.

ProtocolmouseMCP1 
Protocol

To begin assay development using a new matrix, one must first identify an appropriate matrix (or "diluent") for the standards. Linearity experiments and spike-and-recovery experiments were performed to assess whether each proposed matrix is suitable for these sample types. A protocol example may be found in the Application Notes and Poster section below. In Figure 7, the linearity of dilutions in five diluents for spiked mouse BALF (3 ng/mL mTNFα) were examined.

BalfmouseTNFa 
Figure 7. Linearity of five different diluents was determined.

A good diluent will exhibit good recovery (values between 70% and 130%) and linearity (no change upon dilution). In this case, the two best choices are PBS + 0.1% BSA and PBS + 0.01% BSA as demonstrated in Table 3.


AlphaLISA bufferHiBlock bufferPBS + 0.1% BSAPBS + 0.01% BSABeagle BALF
Dilution factor (DF)Recovery from neat (%)Recovery from neat (%)Recovery from neat (%)Recovery from neat (%)Recovery from neat (%)
1100100100100100
2119113959792
4128135939685
8137150909682
16139146929583
32149145949983

Table 3: Linearity results with varying diluents.

To decide which of these two diluents would work best, a spike-and-recovery experiment was performed. Shown in Table 4 are the spike-and-recovery results using PBS + 0.1% BSA as diluents.

alpha_serum_balf_ASK.jpg
Table 4: Excellent recovery was obtained for all four spike concentrations tested. The recovery percentage is equal to the recovery compared to the spiked diluent control.

[*] Concentration for 10 to 3000 pg/mL spikes = measured concentration - no spike value
[**] Recovery (%) = recovery compared to spiked diluent control

For certain sample types, dilutions may be required to achieve good linearity results. In another set of experiments, five diluents were examined for linearity when spiked with 3 ng/mL of mMCP-1 rat AF. In the below chart, the rat amniotic fluid required further sample dilution in order to achieve good linearity. This sample differs from the mouse BALF as shown in Figure 7 which did not require a 2x dilution for good results. It may be necessary to use dilutions to make the samples comparable to the sample being tested.

AFmouseMCP1 
Figure 8. Linearity of five different diluents was determined.

Good recovery (values between 70% and 130%) and linearity (no change upon dilution) are expected once the correct dilution has been determined. The Table 5 summarizes the recovery results obtained.


NaCl bufferPBS + 0.01% BSAHiBlock bufferPBS + 0.1% BSARabbit AF
Dilution factor (DF)Recovery from neat (%)Recovery from 1/2 dil. (%)Recovery from neat (%)Recovery from 1/2 dil. (%)Recovery from neat (%)Recovery from 1/2 dil. (%)Recovery from neat (%)Recovery from 1/2 dil. (%)Recovery from neat (%)Recovery from 1/2 dil. (%)
1100
100
100
100
100
2179100127100144100149100114100
4187104131103157109152102126110
818010012910115410714598123108
1617095129101163113150100116102
32192107129101169117148100119104

Table 5. Tabular results for spiked rat AF assay.

Not a single diluent gave acceptable results from the neat sample, but upon a 1:2 dilution, the two diluents with the best results are HiBlock buffer and PBS with 0.1% BSA, as highlighted by stable recoveries upon dilution and values close to 100%. The diluent showing the best spike-and-recovery was further examined. The concentration for 300-3000 pg/mL spikes is equal to the measured concentration minus the no spike value. The percent recovery is calculated by dividing the value in the sample by the value obtained in the spiked diluent control.

Diluent: PBS + 0.1% BSA

Spike diluent controlSpiked neat Rat AFSpiked 1/2 Rat AF
Spike (pg/mL)Observed concentration (pg/mL)*Observed concentration (pg/mL)*Recovery (%)**Observed concentration (pg/mL)*Recovery (%)**
No spike0.0910.5NA575.6NA
300267.3195.273317.2119
1,000890.5442.650750.484
3,0002,627.61,542.0592,227.985

Table 6. The ½ dilution in diluent required proved excellent recovery for all 3 spikes tested in ½ rat AF, but not in neat rat AF. The measured MCP-1 physiological level in rat AF (No spike) = 575.6 pg/mL X 2 = 1151 pg/mL.

[*] Concentration for 300 to 3000 pg/mL spikes = measured concentration - no spike
[**] Recovery (%) = recovery compared to spiked diluent control

In summary, three cytokines were examined using various sample fluids and diluents. As seen in the below table, lower detection limits were determined along with dilution, spike range and physiological level measured.

AnalyteSample fluidBest diluentLDL in diluent (pg/mL)Dilution of sample fluid required in diluentPhysiological level measured (pg/mL)Spike range in sample fluid giving good recovery (pg/mL)
Mouse IL-6Mouse serumFBS2.11/23330 - 10,000
Mouse BALFPBS + 0.1% BSA2.4Neat2210 - 3,000
Rat CSFBeagle CSF3.4NeatND10 - 3,000
Rat AFPBS + 0.01% BSA2.91/2ND10 - 3,000
Mouse TNFαMouse serumFBS1.61/25530 - 3,000
Mouse BALFPBS + 0.1% BSA1.6Neat1710 - 3,000
Rat CSFPBS + 0.1% BSA1.4NeatND3 - 3,000
Rat AFPBS + 0.01% BSA1.41/253 - 3,000
Mouse MCP-1Mouse serumFBS5.41/2444300 - 3,000
Mouse BALFBeagle BALF5.7Neat501100 - 3,000
Rat CSFPBS + 0.1% BSA2.9Neat501100 - 3,000
Rat AFPBS + 0.01% BSA2.41/21,151300 - 3,000

Table 7. Summary of serum samples and diluent matrices.

Previously published data comparing different serum matrices is included in the table below. Specifically, the physiological level of serum as shown in the above AlphaLISA data in Figure 16 has been compared with the physiological range as reported in the literature. For most sample types, the AlphaLISA results match well with the physiological ranges reported in the literature.


Physiological range found in literature (pg/mL)
CytokineMouse serumMouse BALFRat CSFRat AF
IL-65 - 7020Not found10 - 60
TNFα5 - 10030 - 90Not found10 - 60
MCP-130 - 1,50040Not found1,500

Table 8. Physiological ranges of serum matrices as cited in literature.


Top

Summary


While assay interference is not a general issue with AlphaLISA technology, there is potential that components in complex biological matrices may impact the measured values. The above information is meant to serve as an assay development guide for using Alpha technology with such complex matrices. The assay may require some optimization, including verification that the control matrix is as similar to the sample as possible, selecting appropriate diluent buffer, as well as optimizing the spiking concentration for accurate recovery determinations.

The key points to note when working with serum and other biological matrices in an AlphaLISA assay are as follows.

  • Components of a sample matrix may potentially interfere with an assay.
  • The standard curve of your analyte should be created in a matrix that closely matches the samples.
  • Linearity and spike-and-recovery experiments should be performed to determine if a suggested matrix is suitable for the samples.
  • Sample dilutions may be required in some cases to achieve good results.

Top


Application notes, posters, and protocols


Top


References


Poulsen F and Jensen KB. A Luminescent Oxygen Channeling Immunoassay For The Determination Of Insulin In Human Plasma. J. Biomol. Screen. 12(2), 2007. Link

Petersen, SB et al. Comparison Of Luminescent Oxygen Channeling Immunoassay And ELISA For Detecting Insulin Aspart In Human Serum. J. Pharmaceutical and Biomedical Analysis 51 (2010). Link

Top


Custom conjugation and custom assay development at PerkinElmer


PerkinElmer offers custom bead conjugation services as well as custom assay development. If you are interested in having your biomolecule custom-conjugated to a bead, or in custom assay development, please contact our custom teams:

ON>POINT® Custom Labeling and Conjugation Services
ON>POINT® Custom Assay Development Services